Understanding how individual cancer cells develop in blood cancers.
Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
This study is looking at how certain changes in cancer cells can affect how myeloproliferative neoplasms (MPNs) show up in different patients, with the goal of finding better, personalized treatments based on the unique behavior of each person's cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11009051 on NIH RePORTER |
What this research studies
This research investigates how specific mutations in cancer cells lead to different disease outcomes in patients with myeloproliferative neoplasms (MPNs). By tracing the lineage and differentiation of individual cancer cells, the study aims to identify when and where mutations occur in hematopoietic stem cells. The approach involves profiling each cell to understand the differences between cancerous and healthy cells, which may help explain the variability in disease presentation among patients. This could lead to more personalized treatment strategies based on individual cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms who are experiencing varying disease symptoms.
Not a fit: Patients with other types of blood cancers or those who do not have myeloproliferative neoplasms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more tailored and effective treatments for patients with blood cancers.
How similar studies have performed: Other research has shown promise in understanding cancer cell behavior through lineage tracing, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Hormoz, Sahand — Dana-Farber Cancer Inst
- Study coordinator: Hormoz, Sahand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.